Jarrett Jennifer
Director, President and CEO
Jarrett Jennifer has filed 7 SEC Form 4 filings (12 transaction rows) across 3 companies, including DMRA, SNDX, RCUS, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: Sep 28, 2026.
On the most recent filing, Jarrett Jennifer is listed as Director, President and CEO at Damora Therapeutics, Inc. Inside the rolling window, Jarrett Jennifer reported 1 open-market purchase totaling $253K in DMRA and 3 open-market sales totaling $1.4M in RCUS. The largest disclosed transaction in the window is a sale of 50,291 RCUS shares on Nov 7, 2025, worth $954K.
Companies traded
Other insiders at DMRA
Insider Buying
$253K
reported purchases (SEC code P)
Insider Selling
$1.4M
reported sales (SEC code S)
Companies
3
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
Frequently asked questions
How many SEC Form 4 filings has Jarrett Jennifer made?
Jarrett Jennifer has filed 7 SEC Form 4 filings (12 transaction rows) across 3 companies, including DMRA, SNDX, RCUS since 2025.
Which companies does Jarrett Jennifer trade?
Jarrett Jennifer has filed SEC Form 4 disclosures for 3 companies, including DMRA, SNDX, RCUS.
When was Jarrett Jennifer's most recent SEC Form 4 filing?
Jarrett Jennifer's most recent SEC Form 4 filing on Tracefour is dated Sep 28, 2026.
What is Jarrett Jennifer's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Jarrett Jennifer is listed as Director, President and CEO.
What is Jarrett Jennifer's total buy and sell value in the current window?
Inside the rolling retention window, Jarrett Jennifer bought $253K and sold $1.4M based on SEC Form 4 filings.
What was Jarrett Jennifer's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 50,291 RCUS shares on 2025-11-07, worth $954K, per SEC Form 4 filings.